Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

NCT04967014 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Adult Volunteer

Interventions

DRUG: HIP2101
DRUG: RLD2101

Sponsor

Hanmi Pharmaceutical Company Limited